A detailed history of R Squared LTD transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, R Squared LTD holds 130 shares of TSHA stock, worth $196. This represents 0.0% of its overall portfolio holdings.

Number of Shares
130
Holding current value
$196
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 22, 2025

BUY
$1.27 - $3.24 $165 - $421
130 New
130 $225,000

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $73M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track R Squared LTD Portfolio

Follow R Squared LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of R Squared LTD, based on Form 13F filings with the SEC.

News

Stay updated on R Squared LTD with notifications on news.